CBA
CRVS icon

Coastal Bridge Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Coastal Bridge Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24,000
Closed -$39K – 168
2022
Q1 		$39K Hold
24,000
– – 0.01% 169
2021
Q4 		$58K Buy
+24,000
New +$93.1K 0.01% 198

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Coastal Bridge Advisors's CRVS Position: Q2 2022 in Review

Coastal Bridge Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q2 2022, closing a stake of 24,000 shares — an estimated $39K sold.

Coastal Bridge Advisors first reported a position in CRVS in Q4 2021 and held it in 2 quarters. The position peaked at $58K in Q4 2021. 47 funds tracked by Wall St. Rank hold CRVS as of Q2 2022.

  • Coastal Bridge Advisors reported no remaining Corvus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Coastal Bridge Advisors sold 24,000 Corvus Pharmaceuticals shares in Q2 2022, an estimated $39K.
  • Coastal Bridge Advisors first reported a position in Corvus Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Coastal Bridge Advisors's Corvus Pharmaceuticals position peaked at $58K in Q4 2021.
  • 47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2022.

Based on Coastal Bridge Advisors's 13F filing for Q2 2022, filed 5 Aug 2022.